ClinicalTrials.gg
RecruitingNCT04777760Updated Jul 1, 2025

Surfactant for Neonatal Respiratory Distress Syndrome(NRDS) and Neonatal Acute Respiratory Distress Syndrome(NARDS)

An observational study in Respiratory Distress Syndrome, Preterm Birth and Acute Respiratory Distress Syndrome, sponsored by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University. Recruiting at 1 site in China. Open to participants aged 1 Minute to 24 Hours. Per ClinicalTrials.gov, last updated 2025-07-01.

Sponsored by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Observational

How we know

From the registry’s dates

  • Started Jan 2021; still recruiting 5 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
1 Minute to 24 Hours
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Respiratory Distress Syndrome by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University — 2 open to participants now, 2 under way, none of them phase 3. Respiratory Distress Syndrome · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University.

Started
2021
the only one that year
Observational
2 of 11
1 open now
Registered
11th of 11
by date

Among the 11 studies in Respiratory Distress Syndrome by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, this one is the only one that started in 2021, is one of 2 observational ones, and was the 11th registered.

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

2 of the 11 studies in Respiratory Distress Syndrome by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.

This study: 1 Minute to 24 Hours · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Respiratory Distress Syndrome by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, or all of them as a file.
02

Study summary

In preterm infants with neonatal respiratory distress syndrome (NRDS), exogenous pulmonary surfactant(PS) replacement therapy is one of the most important therapeutic breakthrough to reduce neonatal mortality. Nowadays, PS is commonly used in newborn infants with respiratory distress, but the incidences of bronchopulmonary dysplasia(BPD) and/or death are inconsistent. The result indicates that not all preterm infants with respiratory distress can be beneficial from PS.

In 2017, the international neonatal ARDS (NARDS) collaborative group provides the first consensus definition for NARDS. And whether or not PS being beneficial for preterm infants with NARDS remains unknown.

Read the detailed description

To date, PS is not recommended to adult and pediatric ARDS. Meantime, systematic review indicates that PS does not demonstrate statistically significant beneficial effects on reducing the mortality and the rate of BPD in term and late preterm infants with meconium aspiration syndrome(MAS). Therefore, a reasonable speculation is that preterm infants with NARDS do not benefit from one dose of PS. And the speculation can explain why not all preterm infants with respiratory distress can be beneficial from PS. In the era of pre-NARDS, the preterm infants fulfilling the definition of NARDS may have been considered as NRDS in the first three days after birth.

According to the diagnostic criteria of NARDS, a key procedure for diagnosis of NARDS is to exclude the newborn infants with NRDS. But no detailed procedures are available to differentiate NRDS from NARDS.

03

Conditions studied

  • Respiratory Distress Syndrome
  • Preterm Birth
  • Acute Respiratory Distress Syndrome
  • Surfactant Dysfunction
04

Who can participate

Ages eligible
1 Minute to 24 Hours
Sexes eligible
All
Sampling method
Probability sample

Study population

Preterm infants diagnosed with NRDS or NARDS were eligible. The diagnosis of NARDS was according to the criteria established by Montreux conference in 2017.The diagnosis of NRDS was according to the criteria established by European Consensus Guideline for the management of NRDS in 2019

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Eligibility requirements for neonates were as follows:

  • The gestational age is less than 37 weeks and admitted to neonatal intensive care unit(NICU) in 24 h after birth
  • The neonates will be diagnosed with NRDS or NARDS
  • The neonates will be at least administrated one dose of surfactant

Exclusion criteria

Exclusion Criteria:

one of the following criteria will be needed

  • major congenital anomalies
  • chromosomal abnormalities
  • upper respiratory tract abnormalities
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No

Groups and cohorts

  • one dose of surfactant

    the preterm infants diagnosed with NRDS and/or NARDS will be administrated with only one dose of surfactant

    Drug: one dose of surfactant replacement

  • two and more doses of surfactant

    the preterm infants diagnosed with NRDS and/or NARDS will be administrated with two and more doses of surfactant

    Drug: two and more doses of surfactant replacement

Interventions

  • Drugone dose of surfactant replacement

    the preterm infants diagnosed with NRDS and/or NARDS will be administrated with only one dose of surfactant

  • Drugtwo and more doses of surfactant replacement

    the preterm infants diagnosed with NRDS and/or NARDS will be administrated with two and more doses of surfactant

06

What researchers measure

Primary outcomes

  1. bronchopulmonary dysplasia(BPD)

    the preterm infants will be diagnosed with BPD

    Time frame: at 36 weeks' gestational age or before discharge from hospital

  2. death

    the preterm infants die

    Time frame: at 36 weeks' gestational age or before discharge from hospital

  3. BPD and/or death

    the preterm infants will be diagnosed with BPD and/or death

    Time frame: at 36 weeks' gestational age or before discharge from hospital

  4. the predictive powers of one dose of surfactant to diagnose NRDS

    the sensitivity and accuracy of one dose of surfactant to diagnose NRDS

    Time frame: seven days after birth

  5. the predictive powers of two and more doses of surfactant to diagnose NARDS

    the sensitivity and accuracy of two and more doses of surfactant to diagnose NARDS

    Time frame: seven days after birth

Secondary outcomes

  1. intraventricular hemorrhage(IVH)

    the preterm infants will be diagnosed with IVH

    Time frame: before discharge or 36 weeks' gestational age

  2. air leak

    the preterm infants will be diagnosed with air leak

    Time frame: at 36 weeks' gestational age or before discharge from hospital

  3. periventricular leukomalacia(PVL)

    the preterm infants will be diagnosed with PVL

    Time frame: at 36 weeks' gestational age or before discharge from hospital

  4. necrotizing enterocolitis(NEC)

    the preterm infants will be diagnosed with NEC

    Time frame: at 36 weeks' gestational age or before discharge from hospital

  5. patent ductus arteriosis(PDA)

    the preterm infants will be diagnosed with PDA

    Time frame: at 36 weeks' gestational age or before discharge from hospital

  6. late-onset sepsis(LOS)

    the preterm infants will be diagnosed with LOS

    Time frame: at 36 weeks' gestational age or before discharge from hospital

07

Study locations

1 of 1 sites recruiting
  • Chen
    Chongqing, Chongqing Municipality 400042, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — the data will be accessed after two years of study accomplishment

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: preliminary estimate in 2025

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2021 (actual). Primary completion is estimated for Dec 2026, 71 months after the start.

Of 228 non-industry observational studies under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 71 months is above that.

Counting every sponsor, half of 234 studies reached it within 24 months; a quarter within 12 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2021
First posted
Mar 2, 2021
StartActual
Jan 1, 2021
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04777760
Collaborators
Children's Hospital of Chongqing Medical University
Responsible party
Chen Long,MD (director, Children's Hospital of Chongqing Medical University) — Principal investigator
First posted
Mar 2, 2021
Start date
Jan 1, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 1, 2025

Study contacts

Chen Long, MD, PhD
Contact
neuroclong@126.com
+8613883559467

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion